Alivus Life Sciences Ltd.

The Revenue for the quarter ended  March 2023 of Rs. 6213.20 millions grew by 20.87 % from Rs. 5140.57 millions.An average growth of 47.99% was recorded for the quarter ended March 2023 to Rs. 1463.57  millions from Rs. 988.97 millions.Operating profit for the quarter ended March 2023 rose to 2092.66 millions as compared to 1473.06 millions of corresponding quarter ended March 2022.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202303	202203	% Var	202303	202203	% Var	202303	202203	% Var
Sales	6213.20	5140.57	20.87	21612.20	21232.14	1.79	21612.20	21232.14	1.79
Other Income	28.36	50.95	-44.34	289.57	147.04	96.93	289.57	147.04	96.93
PBIDT	2092.66	1473.06	42.06	6712.50	6307.64	6.42	6712.50	6307.64	6.42
Interest	1.19	1.25	-4.80	5.47	279.62	-98.04	5.47	279.62	-98.04
PBDT	2091.47	1471.81	42.10	6707.03	6028.02	11.26	6707.03	6028.02	11.26
Depreciation	115.17	95.54	20.55	420.94	378.77	11.13	420.94	378.77	11.13
PBT	1976.30	1376.27	43.60	6286.09	5649.25	11.27	6286.09	5649.25	11.27
TAX	512.73	387.30	32.39	1616.48	1462.01	10.57	1616.48	1462.01	10.57
Deferred Tax	39.62	18.25	117.10	110.37	85.74	28.73	110.37	85.74	28.73
PAT	1463.57	988.97	47.99	4669.61	4187.24	11.52	4669.61	4187.24	11.52
Equity	245.05	245.05	0.00	245.05	245.05	0.00	245.05	245.05	0.00
PBIDTM(%)	33.68	28.66	17.54	31.06	29.71	4.55	31.06	29.71	4.55